Literature DB >> 11280755

T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis.

A Hombach1, D Sent, C Schneider, C Heuser, D Koch, C Pohl, B Seliger, H Abken.   

Abstract

Recombinant T-cell receptors with antibody-like specificity are successfully used to direct CTLs toward a MHC-independent immune response against target cells. Here we monitored the specific activation of receptor grafted CTLs in the context of CD28 costimulation. Peripheral blood T cells were retrovirally engrafted with recombinant anti-CD30 and anti-carcinoembryonic antigen receptors, respectively, that harbor either the Fc epsilonRI-gamma or the CD3-zeta intracellular signaling domain. Cross-linking of recombinant receptors by solid-phase bound ligand, i.e., CD30 and a carcinoembryonic antigen receptor-specific anti-idiotypic antibody, respectively, induces IFN-gamma secretion that is further enhanced by CD28 costimulation of grafted T cells. Induction of interleukin (IL)-2 secretion, in contrast, requires CD28 costimulation in addition to receptor cross-linking, irrespective of T-cell preactivation by anti-CD3 monoclonal antibody plus IL-2 or by anti-CD3 monoclonal antibody plus anti-CD28 monoclonal antibody. Accordingly, induction of IL-2 secretion upon receptor cross-linking by membrane-bound antigen requires CD28/B7 costimulation whereas IFN-gamma secretion and cell proliferation does not. The efficiency of cytolysis by receptor-grafted CTLs does not depend on and is not affected by CD28 costimulation. The data demonstrate that CTL proliferation, cytokine secretion, and cytolysis upon receptor cross-linking are differentially modulated by CD28 costimulation and that cytolysis does not require B7 expression on target cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11280755

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

1.  A caspase 8-based suicide switch induces apoptosis in nanobody-directed chimeric receptor expressing T cells.

Authors:  Sepideh Khaleghi; Fatemeh Rahbarizadeh; Davoud Ahmadvand; Mohammad J Rasaee; Philippe Pognonec
Journal:  Int J Hematol       Date:  2012-03-11       Impact factor: 2.490

2.  Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation".

Authors:  Andreas A Hombach; Gunter Rappl; Hinrich Abken
Journal:  Mol Ther       Date:  2013-08-28       Impact factor: 11.454

3.  Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.

Authors:  Evripidis Lanitis; Mathilde Poussin; Alex W Klattenhoff; Degang Song; Raphael Sandaltzopoulos; Carl H June; Daniel J Powell
Journal:  Cancer Immunol Res       Date:  2013-07       Impact factor: 11.151

Review 4.  Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center.

Authors:  Karlo Perica; Kevin J Curran; Renier J Brentjens; Sergio A Giralt
Journal:  Biol Blood Marrow Transplant       Date:  2018-03-01       Impact factor: 5.742

5.  Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors.

Authors:  Thomas M J Niederman; Zoher Ghogawala; Bob S Carter; Hillary S Tompkins; Margaret M Russell; Richard C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-07       Impact factor: 11.205

6.  PTPN22 1858C>T (R620W) functional polymorphism and human longevity.

Authors:  Valerio Napolioni; Annalia Natali; Patrizia Saccucci; Nazzareno Lucarini
Journal:  Mol Biol Rep       Date:  2010-11-27       Impact factor: 2.316

Review 7.  Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.

Authors:  William R Strohl; Michael Naso
Journal:  Antibodies (Basel)       Date:  2019-07-03

Review 8.  Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.

Authors:  Marc Cartellieri; Michael Bachmann; Anja Feldmann; Claudia Bippes; Slava Stamova; Rebekka Wehner; Achim Temme; Marc Schmitz
Journal:  J Biomed Biotechnol       Date:  2010-05-05

Review 9.  The promise and potential pitfalls of chimeric antigen receptors.

Authors:  Michel Sadelain; Renier Brentjens; Isabelle Rivière
Journal:  Curr Opin Immunol       Date:  2009-03-25       Impact factor: 7.486

10.  Coexpressed Catalase Protects Chimeric Antigen Receptor-Redirected T Cells as well as Bystander Cells from Oxidative Stress-Induced Loss of Antitumor Activity.

Authors:  Maarten A Ligtenberg; Dimitrios Mougiakakos; Madhura Mukhopadhyay; Kristina Witt; Alvaro Lladser; Markus Chmielewski; Tobias Riet; Hinrich Abken; Rolf Kiessling
Journal:  J Immunol       Date:  2015-12-16       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.